OpportunityAnalyzer: Celiac DiseaseOpportunity Analysis and Forecast to 2023
Single User License - $7995 Site User License - $15995 Corporate User License - $23985 Publication Date - Nov 2014 Pages - 165 To know more details, email to debora@reportstack.com
Contact: debora@reportstack.com Reportstack Market Research
Summary ď ś There are no pharmacological treatments that are indicated for celiac disease and the current standard of care treatment involves a gluten free diet (GFD). Steroids and immunosuppressants are used to reduce symptoms in severe cases, targeting approximately 5% of the celiac disease patient population and there are no preventative medications. The anticipated launch of Alba/Teva’s larazotide acetate in 2018 in the US and 2019 in 5EU, followed by the launch of Alvine/AbbVie’s latiglutenase in 2019 and 2020 in the US and 5EU respectively are set to change the management of the disease and drive growth in the celiac disease market.
Contact: debora@reportstack.com Reportstack Market Research
Key Findings - High uptake is expected of pipeline drugs for celiac disease that are anticipated to launch during the 2013-2023 forecast period. - Celiac disease remains a field of highly unattained unmet need. - There is no consensus over clinical trial design and endpoints for the development of celiac disease products. - The clinical stage pipeline is mainly focussed on GFD adjunctive therapies, while the pre-clinical stage pipeline has shifted its focus to disease modifying treatments. - Significant opportunity exists for products targeting in the nonrefractory patient segment of the celiac disease market.
Contact: debora@reportstack.com Reportstack Market Research
Scope - Overview of celiac disease, including epidemiology, etiology, pathophysiology, symptoms and current treatment options - Annualized celiac disease therapeutics market revenue, annual cost of therapies and forecasts for five years to 2018 and ten years to 2023. - Key topics covered include strategic product assessment, market characterization, unmet needs, R&D strategies, clinical trial design and implications for the celiac disease therapeutics market. - Pipeline analysis: comprehensive data split across different phases, emerging trends and mechanisms of action under development, including zonulin inhibitors, gluten peptide enzymes, gluten specific synthetic polymers and therapeutic vaccines. Contact: debora@reportstack.com Reportstack Market Research
Key Benefits - Identify the unmet needs and remaining opportunities in the celiac disease therapeutics market. - Develop business strategies by understanding the trends shaping and driving the US and five major EU celiac disease therapeutics market. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Assess the clinical and commercial viability of promising pipeline products. - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies.
Contact: debora@reportstack.com Reportstack Market Research
If you are interested...
Contact : Debora White Email: debora@reportstack.com Ph:+1-888-789-6604 http://www.reportstack.com
Contact: debora@reportstack.com Reportstack Market Research